First Trust NASDAQ 100 Technology Index Fund vs Sanofi SA — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $306.13, while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA pays a 5.53% dividend while First Trust NASDAQ 100 Technology Index Fund pays none, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| QTEC | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $335.74 | $52.34 |
52-Week Low | $207.03 | $41.33 |
Market Cap | — | $104.85B |
Enterprise Value | — | $121.38B |
Dividend Yield | — | 5.53% |
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $301.50, up 0.53% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $285. Recent news highlights its role as a smart beta ETF providing broad technology sector exposure since its 2006 launch, though some reports question if recent large sales signal caution around overheated AI and chip stocks.
The ETF's outlook is clouded by bearish technicals and sector concentration risks, but its equal-weighted access to top tech firms offers targeted exposure. Key risks include market volatility and sector-specific headwinds, while the neutral oscillator readings suggest potential for stabilization near current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →